Medical therapy for Crohn's disease strictures

Inflammatory Bowel Diseases

Volumn 10, Issue 1, 2004, Pages 55-60

  Van Assche, Gert ^a   Geboes, Karel ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Crohn's disease; Intestinal stenosis; TGF

Indexed keywords

GROWTH FACTOR; INTERLEUKIN 10; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; VERAPAMIL;

ANTIINFLAMMATORY ACTIVITY; BALLOON DILATATION; CELL ACTIVATION; CROHN DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; EPITHELIUM CELL; FIBROGENESIS; HUMAN; INTESTINAL FIBROSIS; INTESTINE ENDOSCOPY; INTESTINE MUSCLE; INTESTINE RESECTION; INTESTINE STENOSIS; LEUKOCYTE; LIVER; MESENCHYME CELL; NONHUMAN; PATIENT SELECTION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SHORT BOWEL SYNDROME; SMALL INTESTINE OBSTRUCTION; SUBMUCOSA; TREATMENT OUTCOME;

BALLOON DILATATION; COLONOSCOPY; CROHN DISEASE; HUMANS; INTESTINAL OBSTRUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 0346656704     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200401000-00009     Document Type: Review

References (56)

1. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990;99:956-963.
2. Pucilowska JB, Williams KL, Lund PK. Fibrosis in inflammatory bowel disease: cellular mediators and animal models. Am J Physiol. 2000;279: G653-G659.
3. Verrechia F, Mauviel A. TGF-β signaling throuh the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol. 2002;118:211-215.
4. di Mola. Friess H, Scheuren A et al. TGF-βs and their signaling receptors are coexpressed in Crohn's disease. Ann. Surgery. 1999;229:67-75.
5. Fiocchi C. TGF-β/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation. J Clin Invest. 2001;108:523-526.
6. Monteleone G, Kumberova A, Croft N, et al. Blocking Smad7 restores TGF-β signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108:601-609.
7. Yang X, Letterio JJ, Lechleider RJ, et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. EMBO J. 1999;18:1280-1291.
8. Ulloa L, Doody J, Massagué J. Inhibition of TGF-β/Smad signalling by the interferon-γ/STAT pathway. Nature. 1999;397:710-713.
9. D'haens G. Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology. 1999;116:1029-1034.
10. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology. 1999;116:22-28.
11. Moustakas A, Pardali K, Gaal A, et al. Mechanisms of TGF-□ signaling in regulation of cell growth and differentiation. Immunol Lett. 2002;82: 85-91.
12. Babyatski NW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic muoca in inflammatory bowel disease. Gastroenterology. 1996;110:975-984.
13. McKaig BC, Hughes K, Tighe PJ, et al. Differential expression of TGF-isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol. 2002;282:C172-C182.
14. Regan MC, Flavin BM, Fitzpatrick JM, et al. Stricture formation in Crohn's disease. The role of intestinal fibroblasts. Ann Surg. 2000;231: 46-50.
15. Martin P. Wound healing - Aiming for perfect skin regeneration. Science. 1997;276:75-81.
16. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med. 1999; 340:115-126.
17. Graham MF. Pathogenesis of intestinal strictures in Crohn's disease. Inflamm Bowel Dis. 1995;1:220-227.
18. Lund PK. The alpha-smooth muscle promoter: a useful tool to analyse autocrine and paracrine roles of mesenchymal cells in normal and diseased bowel. Gut. 1998;42:320-322.
19. Graham MF, Willey A, Adams J, et al. IL-1 down-regulates collagen and augments collagenase expression in intestinal smooth muscle cells. Gastroenterology. 1996;110:344-350.
20. Schuppan D, Hahn EG. MMPs in the gut: inflammation hits the matrix. Gut. 2000;47:12-14.
21. von Lampe B, Barthel B, Coupland SE, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut. 2000;47:63-73.
22. Louis E, Ribbens C, Godon A, et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed muocsa in inflammatory bowel disease. Clin Exp Immunol. 2000;120: 241-246.
23. Lawrance IC, West G, Willis J, et al. A novel murine method of chronic inflammation induced intestinal fibrosis. Gastroenterology. 2000;118: A575.
24. Van Tol EA, Holt L, Feng LF, et al. Bacterial cell wall polymers promote intestinal fibrosis by direct stimulation of myofibroblasts. Am J Physiol. 1999;277:G245-G255.
25. Plateroti M, Rubin DC, Duluc I, et al. Subepithelial fibroblast cell lines from different levels of the gut axis display regional characteristics. Am J Physiol. 1998;274:G945-G954.
26. Stallmach A, Schuppan D, Riese HH, et al. Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease. Gastroenterology. 1992;102:1920-1929.
27. Brannigan AE, Watson RW, Beddy D, et al. Increased adhesion molecule expression in serosal fibroblasts isolated from patients with inflammatory bowel disease is secondary to inflammation. Ann Surg. 2002;235:507-511.
28. McKaig BC, McWilliams D, Watson SA, Mahida YR. Expression and regulation of tissue inihibitor of metalloproteinase-1 and maatrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol. 2003;162:1355-1360.
29. Zhou A, Ueno H, Shimomura M, et al. Blockade of TGF-beta action ameliorates renal dysfunction and histologic progression in anti-GBM nephritis. Kidney Int. 2003;64:92-101.
30. Cordeiro MF, Gay JA, Khaw PT. Human anti-transforming growth factor beta2 antibody: a new glaucoma anti-scarring agent. Invest Opthalmol Vis. Sci. 1999;40:2225-2234.
31. Motomura Y, Kambayashi H, Deng Y, et al. The effects of gene transfer of soluble TGF-b type II receptor and soluble VEGF type I receptor (Flt-1) in peritoneal fibrosis model of mice: balance between inflammation and fibrosis. Gastroenterology. 2003;124:A339. (abstract)
32. Zanninelli G, Wengrower D, Pappo O, et al. Captopril prevents intestinal fibrosis by TGF-b1 downregulation in TNBS colitis in rats. Inflam Bowel Dis. 2003;9:S39. (abstract)
33. Scheinfeld BA, Collins SM, Blennerhasset MG. Verapamil inhibits interleukin-1b mediated hyperplasia of human intestinal smooth muscle cells. Gastroenterology. 1994;106:A768.
34. Van Assche G, Depoortere I, de Vos R, et al. Region specific anti-proliferative effect of VIP and PACAP38 on rabbit enteric smooth muscle. Am J Physiol. 1999;276:G303-G310.
35. Jobson TM, Billinton CK, Hall IP. Regulation of proliferation of human colonic subepithelial myofibroblasts by mediators important in intestinal inflammation. J Clin Invest. 1998;101:2650-2657.
36. Billington CK, Joseph SK, Swan C, et al. Modulation of human airway smooth muscle proliferation by type 3 phosphodiesterase inhibition. Am J Physiol. 1999;276:L412-L419.
37. Kernochan et al. Endothelin-1 stimulates human colonic myofibroblast contraction and migration. Gut 2002;50:65-70.
38. Siegmund B, Lehr HA, Fantuzzi G. Leptin: A pivotal mediator in intestinal inflammation in mice. Gastroenterology. 2002;122:2011-2025.
39. Wu KK. Prostacyclin and nitric oxide-related gene transfer in preventing arterial thrombosis and restenosis. Agents Actions Suppl. 1997;48:107-123.
40. Owens GK, Wise G. Regulation of differentiation/maturation in vascular smooth muscle cells by hormones and growth factors. Agents Actions Suppl. 1997;48:3-24.
41. Sabaté JM, Lemann M. Traitement endoscopique des sténoses dans la maladie de Crohn. Hépato-gastro. 2002;9:169-173.
42. Bedogni G, Ricci E, Pedrazolli C, et al. Endoscopic dilation of anastomotic colonic stenosis by different techniques: an alternative to surgery? Gastrointest Endosc. 1987;33:21-24.
43. Matsuhashi N, Nakajima A, Suzuki A, et al. Long-term outcome of non-surgical strictureplasty using metallic stents for intestinal strictures in Crohn's disease. Gastrointest Endoscopy. 2000;51:343-345.
44. Blomberg B, Rolny P, Jamerot G. Endoscopic treatment of anastomotic strictures in Crohn's disease. Endoscopy. 1991;23:195-198.
45. Couckuyt H, Gevers AM, Coremans G, et al. Efficacy and safety of hydrostatic balloon dilatation of ileocolonic Crohn's strictures: a prospective longterm analysis. Gut. 1995;36:577-580.
46. Sabate JM, Villarejo J, Lemann M, et al. Hydrostatic balloon dilatation of Crohn's strictures. Gastroenterology. 2001;120:A449. (abstract)
47. Ramboer C, Verhamme M, Dhondt E, et al. Endoscopic treatment of stenosis in recurrent Crohn's disease with balloon dilation combined with local corticosteroid injection. Gastrointest Endosc. 1995;42:252-255.
48. Dear KL, Hunter JO. Colonoscopic hydrostatic balloon dilatation of Crohn's strictures. J Clin Gastroenterol. 2001;33:315-318.
49. Junge U, Zuchner H. Endoscopic balloon dilatation of symptomatic strictures in Crohn's disease. Dtsch Med Wochenschr. 1994;119:1377-1382.
50. Raedler A, Peters I, Schreiber S. Treatment with azathioprine and budesonide prevents reoccurrence of ileocolonic stenoses after endoscopic dilatation in Crohn's disease. Gastroenterology. 1997;112:A1067. (abstract)
51. Lavy A. Triamcinolone improves outcome in Crohn's disease strictures. Dis Colon Rectum. 1997;40:184-186.
52. Brooker JC, Beckett CC, Saunders BP, et al. Long-acting steroid injections after endoscopic dilation of anastomotic Crohn's strictures may improve outcome: a retrospective case series. Endosopy. 2003;35:333-337.
53. Thomas-Gibson S, Brooker JC, Hayward CM, et al. Colonoscopic balloon dilation of Crohn's strictures: a review of long-term outcomes. Eur J Gastroenterol Hepatol. 2003;15:485-488.
54. Lawrance IC, Maxwell L, Doe W. Altered response of intestinal mucosal fibroblasts to fibrogenic cytokines in inflammatory bowel disease. Inflamm Bowel Dis. 2001;7:226-236.
55. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;25:1352-1355.
56. Perr HA, Graham MF, Diegelmann RF, et al. Cyclic nucleotides regulate collagen production by human smooth muscle cells. Gastroenterology. 1989;96:1521-1528.